Vaxcyte Inc reports results for the quarter ended in December - Earnings Summary

Vaxcyte

27/02/2024 23:22

* Vaxcyte Inc  PCVX.OQ  reported a quarterly adjusted loss
of
$1.82​​ per share for the quarter ended in December, lower than
the same quarter last year, when the company reported EPS of
$-1.02.  The mean expectation of eight analysts for the quarter
was for a loss of $1.07 per share. Wall Street expected
results to range from $-1.61 to -54 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Vaxcyte Inc's reported EPS for the quarter was a loss of
$1.82​.
    * The company reported a quarterly loss of $180.8 million.
    * Vaxcyte Inc shares had risen by 25.7% this quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 1.3%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 8 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * Wall Street's median 12-month price target for Vaxcyte Inc
is
$76.00 

This summary was machine generated from LSEG data February 27 at
11:22 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -1.07          -1.82          Missed
 Sep. 30 2023      -0.84          -0.91          Missed
 Jun. 30 2023      -0.74          -0.70          Beat
 Mar. 31 2023      -0.83          -0.70          Beat